# Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.

> **NCT06553287** · PHASE1 · COMPLETED · sponsor: **Lynk Pharmaceuticals Co., Ltd** · enrollment: 28 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** LNK01004 ointment 0.3%
- **DRUG:** LNK01004 ointment 1.0%
- **DRUG:** LNK01004 ointment 1.5%
- **DRUG:** Vehicle BID

## Key facts

- **NCT ID:** NCT06553287
- **Lead sponsor:** Lynk Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-12
- **Primary completion:** 2024-06-18
- **Final completion:** 2024-06-18
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06553287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06553287, "Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT06553287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*